Robert Šeparović

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Expression of Cancer/Testis Tumor Associated Antigens in Cervical Squamous Cell Carcinoma

Božena Šarčević, Giulio C. Spagnoli, Luigi Terracciano et al. · Oncology · 2003 · 33 citations

Immunohistochemical Analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR Antigen Expression in Medullary Breast Cancer

Božica Matković, Antonio Juretić, Viktor Šeparović et al. · Tumori Journal · 2008 · 28 citations

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Stephen Chia, Miguel Martín, Frankie A. Holmes et al. · Breast Cancer Research · 2019 · 28 citations · Full text

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

Frankie A. Holmes, Beverly Moy, Suzette Delaloge et al. · European Journal of Cancer · 2023 · 27 citations · Full text